AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus paradisi peel extract
Number of subjects: 0
Study 19153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus paradisi juice
Number of subjects: 0
Study 17060046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (continuous infusion of 1.5 mg/kg per hour during operation)
Number of subjects: 30
Study 17060046 — intervention group
Group type: COMPARATOR
Intervention: Control (no pentoxifylline)
Number of subjects: 30
Study 13129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months neo-adjuvant maximal androgen deprivation (MAD) with goserelin and flutamide
Number of subjects: 818
Study 13129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months neo-adjuvant maximal androgen deprivation (MAD) with goserelin and flutamide
Number of subjects: 818
Study 13129633 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term neo-adjuvant MAD
Number of subjects: 818
Study 13129633 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term goserelin
Number of subjects: 818
Study 13129633 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms (including radiation treatment alone)
Number of subjects: 818
Study 13129633 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term MAD
Number of subjects: 818
Study 10638985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist), preoperative administration, dosage and duration not specified
Number of subjects: 0
Study 10638985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist), preoperative administration
Number of subjects: 0
Study 9344321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rTNF alpha + interferon-gamma + melphalan
Number of subjects: 140
Study 9344321 — intervention group
Group type: COMPARATOR
Intervention: TNF alpha + melphalan
Number of subjects: 140
Study 1526756 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (ST)
Number of subjects: 34
Study 1526756 — intervention group
Group type: COMPARATOR
Intervention: Long-term dynamic psychotherapy (LT)
Number of subjects: 34
Study 2863393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal injection of 5 mg phentolamine
Number of subjects: 10
Study 2863393 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing upright
Number of subjects: 10
Study 2863393 — intervention group
Group type: EXPERIMENTAL
Intervention: Assuming a supine posture
Number of subjects: 10
Study 29580959 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive tactile stimulation
Number of subjects: 0
Study 29580959 — intervention group
Group type: COMPARATOR
Intervention: Standard stimulation
Number of subjects: 0
Study 28793884 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 60
Study 28793884 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 60
Study 28793884 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (control group)
Number of subjects: 60
Study 26523886 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Project
Number of subjects: 66
Study 26523886 — intervention group
Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 66
Study 24055246 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish UPSA (Sp-UPSA)
Number of subjects: 227
Study 20803065 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC90 ×6 cycles
Number of subjects: 1246
Study 20803065 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC90 ×4 cycles followed by eight doses of weekly paclitaxel (T)
Number of subjects: 1246
Study 20803065 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC90
Number of subjects: 1246
Study 20803065 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (T)
Number of subjects: 1246
Study 18226794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio production experiment with variable circles
Number of subjects: 10
Study 17009401 — intervention group
Group type: EXPERIMENTAL
Intervention: S-pantoprazole (20 mg once a day)
Number of subjects: 369
Study 17009401 — intervention group
Group type: COMPARATOR
Intervention: racemic pantoprazole (40 mg once a day)
Number of subjects: 369
Study 15213583 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus multimodal psychosocial treatment (including social skills training)
Number of subjects: 103
Study 15213583 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103
Study 15213583 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103
Study 11257276 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking with GSTT1-1 genotype
Number of subjects: 1489
Study 11257276 — intervention group
Group type: EXPERIMENTAL
Intervention: 20+ pack-years with GSTT1-1 genotype
Number of subjects: 1489
Study 11257276 — intervention group
Group type: COMPARATOR
Intervention: Current smoking with GSTT1-0 genotype
Number of subjects: 1489
Study 11257276 — intervention group
Group type: COMPARATOR
Intervention: 20+ pack-years with GSTT1-0 genotype
Number of subjects: 1489
Study 9625397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet
Number of subjects: 605
Study 9625397 — intervention group
Group type: COMPARATOR
Intervention: Control diet (American Heart Association prudent diet)
Number of subjects: 605
Study 7917930 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g of glutamine per day for 8 days
Number of subjects: 28
Study 7917930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) administered postoperatively in incremental doses up to 1 mg
Number of subjects: 59
Study 3140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) administered postoperatively
Number of subjects: 59
Study 31834117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cycled light
Number of subjects: 0
Study 31834117 — intervention group
Group type: COMPARATOR
Intervention: Late cycled light
Number of subjects: 0
Study 31834117 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed feeding progression
Number of subjects: 0
Study 31834117 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical feeding progression
Number of subjects: 0
Study 30336601 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping time
Number of subjects: 435
Study 30336601 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocating time from any behaviour to stepping
Number of subjects: 435
Study 30336601 — intervention group
Group type: EXPERIMENTAL
Intervention: Relocating time from stepping into sleep, sitting, or standing
Number of subjects: 435
Study 27756395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological markers (Pf.GLURP.R2, Pf.MSP1.19, CSP, PvAMA1)
Number of subjects: 6502
Study 27756395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological markers
Number of subjects: 6502
Study 27756395 — intervention group
Group type: COMPARATOR
Intervention: PCR prevalence and malaria incidence data
Number of subjects: 6502
Study 24333186 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 14
Study 24333186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24198581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 96
Study 24198581 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 20849801 — intervention group
Group type: EXPERIMENTAL
Intervention: Callos calcium phosphate cement (CPC)
Number of subjects: 26
Study 18838750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine sulphate 10 mg
Number of subjects: 60
Study 18838750 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac suppository 100 mg
Number of subjects: 60
Study 16652054 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) and adherence support (AT)
Number of subjects: 122
Study 16652054 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 122
Study 12958329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril (4 mg/d) and diuretic indapamide (as needed)
Number of subjects: 6105
Study 12958329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 10980588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 500 mg daily for 7 days
Number of subjects: 7
Study 10980588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 1 g daily for a further 7 days
Number of subjects: 7
Study 10980588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8628544 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 268
Study 8628544 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 268
Study 1611830 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Tolerance Test (ITT) with 0.1 U kg‐1 body weight, human Actrapid insulin given as an IV bolus; KITT measured over the period 3-15 min.
Number of subjects: 17
Study 1611830 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemic clamp with insulin infusion of 50 mU kg‐1 h‐1 for 120 min; M/I values derived from the clamp.
Number of subjects: 17
Study 31177595 — intervention group
Group type: EXPERIMENTAL
Intervention: TLL1 AA genotype (329 patients)
Number of subjects: 452
Study 31177595 — intervention group
Group type: EXPERIMENTAL
Intervention: TLL1 AT/TT genotype (123 patients)
Number of subjects: 452
Study 31177595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (452 patients)
Number of subjects: 452
Study 31177595 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncirrhotic patients (348 patients)
Number of subjects: 452
Study 31177595 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors (Male sex, Diabetes, FIB-4 score)
Number of subjects: 452
Study 29301520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for 6 weeks
Number of subjects: 59
Study 26575250 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Number of subjects: 2313
Study 26575250 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Number of subjects: 2313
Study 26575250 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100mg
Number of subjects: 2313
Study 23789873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono‐HA
Number of subjects: 0
Study 23789873 — intervention group
Group type: COMPARATOR
Intervention: Bi‐HA
Number of subjects: 0
Study 22782041 — intervention group
Group type: COMPARATOR
Intervention: Scaling/root planing only
Number of subjects: 25
Study 22782041 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling/root planing followed by minocycline placement
Number of subjects: 25
Study 22782041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival papilla reflection followed by scaling/root planing and flap closure
Number of subjects: 25
Study 22782041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival papilla reflection, scaling/root planing, minocycline placement, and flap closure
Number of subjects: 25
Study 20729538 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (75 mg once a day before and during IVF treatment)
Number of subjects: 33
Study 20729538 — intervention group
Group type: COMPARATOR
Intervention: Control (no DHEA supplementation)
Number of subjects: 33
Study 18685496 — intervention group
Group type: EXPERIMENTAL
Intervention: VT insertion with adjuvant adenoidectomy
Number of subjects: 541
Study 18685496 — intervention group
Group type: EXPERIMENTAL
Intervention: VT insertion without adjuvant adenoidectomy
Number of subjects: 541
Study 18685496 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical observation
Number of subjects: 541
Study 18685496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postintervention Veq difference
Number of subjects: 541
Study 18685496 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Veq
Number of subjects: 541
Study 15714184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (15 microg)
Number of subjects: 62
Study 15714184 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 62
Study 15314402 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 0
Study 15314402 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 0
Study 10665626 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex oral loading (30 mg/kg/day on days 1 and 2, followed by 20 mg/kg/day on days 3‐10)
Number of subjects: 59
Study 10665626 — intervention group
Group type: COMPARATOR
Intervention: Divalproex nonloading (starting dose of 250 mg t.i.d. on days 1 and 2, followed by standard dose titration for days 3 to 10)
Number of subjects: 59
Study 10665626 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (starting dose of 300 mg t.i.d., followed by standard dose titration for days 3 to 10)
Number of subjects: 59
Study 8889672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (1.2 mg)
Number of subjects: 6
Study 8889672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (4.0 mg)
Number of subjects: 6
Study 8889672 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal buprenorphine (4.0 mg)
Number of subjects: 6
Study 8889672 — intervention group
Group type: EXPERIMENTAL
Intervention: Norbuprenorphine (all routes)
Number of subjects: 6
Study 2057467 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 989
Study 2057467 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 989
Study 3928820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 181
Study 3928820 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 181
Study 3928820 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 181
Study 31780034 — intervention group
Group type: EXPERIMENTAL
Intervention: Qing-Xin-Jie-Yu Granule (QXJYG)
Number of subjects: 1500
Study 31780034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 29706008 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 989
Study 29706008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 29706008 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 989
Study 27398953 — intervention group
Group type: EXPERIMENTAL
Intervention: PIB converters (n=20)
Number of subjects: 164
Study 27398953 — intervention group
Group type: COMPARATOR
Intervention: PIB-negative individuals (n=123)
Number of subjects: 164
Study 27398953 — intervention group
Group type: EXPERIMENTAL
Intervention: PIB-positive individuals (n=21)
Number of subjects: 164
Study 27398953 — intervention group
Group type: COMPARATOR
Intervention: Stable PIB(-) group
Number of subjects: 164
Study 27398953 — intervention group
Group type: EXPERIMENTAL
Intervention: Early symptomatic AD group (n=10)
Number of subjects: 164
Study 25299437 — intervention group
Group type: EXPERIMENTAL
Intervention: Play fighting
Number of subjects: 210
Study 25299437 — intervention group
Group type: COMPARATOR
Intervention: Volleyball (control)
Number of subjects: 210
Study 22120044 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg cocoa flavanols
Number of subjects: 63
Study 22120044 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cocoa flavanols
Number of subjects: 63
Study 22120044 — intervention group
Group type: COMPARATOR
Intervention: Low cocoa flavanol (placebo) drink
Number of subjects: 63
Study 19878615 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week blueberry and apple juice intervention
Number of subjects: 168
Study 22751370 — intervention group
Group type: COMPARATOR
Intervention: Nomogram-directed glucose control
Number of subjects: 34
Study 22751370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed glucose control
Number of subjects: 34
Study 15939621 — intervention group
Group type: EXPERIMENTAL
Intervention: CCECC
Number of subjects: 30
Study 15939621 — intervention group
Group type: COMPARATOR
Intervention: CPB
Number of subjects: 30
Study 15939621 — intervention group
Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 30
Study 12883399 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam administered extracorporeally (into the circuit)
Number of subjects: 20
Study 12883399 — intervention group
Group type: COMPARATOR
Intervention: Midazolam administered via central or peripheral access
Number of subjects: 20
Study 9531857 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation (8 times over 4 weeks)
Number of subjects: 34
Study 9531857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UV exposure)
Number of subjects: 34
Study 7651559 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (3 x 20 mg daily)
Number of subjects: 60
Study 7651559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (3 x 8 mg daily)
Number of subjects: 60
Study 7651559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2759694 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein milk (3.1 g/100 ml)
Number of subjects: 0
Study 2759694 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 0
Study 1195660 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labelled sulfur colloid
Number of subjects: 18
Study 1195660 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed vagolytic substance
Number of subjects: 18
Study 31743193 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with 2.5 mL/kg of 0.2% ropivacaine
Number of subjects: 152
Study 31743193 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.9% saline
Number of subjects: 152
Study 31743193 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with 0.2% ropivacaine
Number of subjects: 152
Study 28844191 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the first non-surgical phase (T1)
Number of subjects: 80
Study 28844191 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the second surgical phase (T2)
Number of subjects: 80
Study 28844191 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including four parameters
Number of subjects: 80
Study 28844191 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Parvimonas micra before therapy
Number of subjects: 80
Study 25310295 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 113
Study 25310295 — intervention group
Group type: EXPERIMENTAL
Intervention: DAST
Number of subjects: 113
Study 24146646 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 70
Study 24146646 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 70
Study 24146646 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 70
Study 24146646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22303705 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) 200 mL (50 mL SI in 200 mL normal saline)
Number of subjects: 100
Study 22303705 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 mL normal saline)
Number of subjects: 100
Study 22303705 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI)
Number of subjects: 100
Study 22303705 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 18325114 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised and supervised exercise programme (PEP) plus manual auricular acupuncture for 6 weeks
Number of subjects: 80
Study 18325114 — intervention group
Group type: COMPARATOR
Intervention: Personalised and supervised exercise programme (PEP) alone for 6 weeks
Number of subjects: 80
Study 16567436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen use
Number of subjects: 99
Study 16567436 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-tamoxifen discontinuation
Number of subjects: 99
Study 12706366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) Index and personal ultraviolet radiation (UVR) intensity indicator
Number of subjects: 3200
Study 12706366 — intervention group
Group type: COMPARATOR
Intervention: General, written information about sun protection
Number of subjects: 3200
Study 10912888 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (5,000 U, 3 times weekly for 4 weeks)
Number of subjects: 20
Study 10912888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8826493 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal lumbosacral root blocks
Number of subjects: 33
Study 8826493 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch posterior primary ramus blocks
Number of subjects: 33
Study 8826493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve blocks
Number of subjects: 33
Study 8826493 — intervention group
Group type: COMPARATOR
Intervention: Control: lumbar subcutaneous injection of 3 ml of 0.5% bupivacaine
Number of subjects: 33
Study 1317525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 0
Study 1317525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan membrane
Number of subjects: 0
Study 1317525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate membrane
Number of subjects: 0
Study 1317525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membrane
Number of subjects: 0
Study 3862341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pterygoid muscle extirpation
Number of subjects: 21
Study 3862341 — intervention group
Group type: COMPARATOR
Intervention: Control side (intact lateral pterygoid muscle)
Number of subjects: 21
Study 3862341 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental side (lateral pterygoid muscle extirpated)
Number of subjects: 21
Study 3862341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sides (control and experimental)
Number of subjects: 21